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Abstract Tuberculosis (TB) is an airborne infectious disease that is both pre-
ventable and curable, yet it kills more than a million people every year. Children are
highly vulnerable, but often invisible casualties. Drug-resistant forms of TB are on the
rise globally, and children are as vulnerable as adults but less likely to be counted as
cases of drug-resistant disease if they become sick. Four factors make children with
drug-resistant TB ‘invisible’: first, the nature of the disease in children; second, defi-
ciencies in existing diagnostic tools; third, overreliance on these tools; and fourth, our
collective failure to deploy one effective tool for finding and treating children – contact
investigation. We describe a nascent science-advocacy network – the Sentinel Project
on Pediatric Drug-Resistant Tuberculosis –whose goal is to end child deaths from this
disease. Provisional annual targets, focused on children exposed at home to multi-
drug-resistant TB, to be updated every year, constitute a framework to focus attention
and collective actions at the community, national, and global levels. The targets in two
age groups, under 5 and 5–14 years old, tell us the number of: (i) children who require
complete evaluation for TB disease and infection; (ii) children who require treatment
for TB disease; and (iii) children who would benefit from preventive therapy.
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Introduction
Burden of tuberculosis (TB) and drug resistance
The global burden of TB disease is enormous. In 2012, the World Health
Organization estimated that 8.6 million people became sick with TB
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(new cases) and 1.3 million people died from TB.1 At least 1 million
children become sick with TB every year,2,3 and at least 8 million
children are infected every year.4 In any year, children in high
TB-burdened communities account for more than 25 per cent of all
those who become sick with TB.5,6
Drug-resistant tuberculosis (DR-TB) is defined as disease caused by an
M. tuberculosis strain resistant to one or more TB drugs. A subset,
multidrug-resistant TB (MDR-TB), is caused by a strain resistant to at
least isoniazid and rifampin, the two drugs that presently form the basis
of first-line therapy. Strains resistant to more drugs have been called
extensively drug-resistant TB (XDR-TB) or totally drug-resistant TB
(TDR-TB), both subsets of MDR-TB. WHO estimates that at least
half a million people become sick with MDR-TB each year.1 Official
estimates of all forms of DR-TB probably grossly underestimate the true
burden of this problem.7–12 A recent survey in China suggests a much
larger DR-TB disease burden than expected.13 China, along with India
and Russia, are thought to bear about 60 per cent of the global burden of
MDR-TB disease.1
The work we describe here began after an April 2011 workshop in
Delhi to examine barriers to scaling up treatment for DR-TB in India.10
Other workshops to better understand DR-TB in South Africa, Russia,
and China8–10,12 all drew attention to a hidden epidemic of DR-TB in
children. The Delhi workshop led us to grasp that the near invisibility
everywhere of children with DR-TB was itself a barrier to expanded
research and improved treatment access.
Our systematic review14 found that children sick with isoniazid-
resistant TB have been reported in at least 40 countries. WHO surveil-
lance reports make it clear that MDR-TB is as common in children as in
adults, yet government reports capture very few children with the
disease.15 The first estimates of how many children become sick with
MDR-TB each year suggest 32 000 (95 per cent CI: 26 000–39 000).3
No one has estimated the larger number of children who become sick
with other forms of DR-TB.
TB Treatment Saves Lives and Prevents New Infections, but
Access to DR-TB Treatment is Limited
TB is curable, even highly drug-resistant M. tuberculosis. Nearly all
those sick with TB organisms susceptible to first-line drugs can be cured.
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When someone is sick with a drug-resistant strain, cure remains possible
using drugs to which the infecting strain is susceptible. Knowing which
drugs to use, however, requires the sick person’s strain be isolated and
tested for drug-susceptibility.
At least 60 per cent of those sick with MDR-TB can be cured using
existing drugs; some programs have achieved better than 75 per cent
cure.16 Children with MDR-TB do better than adults, with cure achieved
in over 80 per cent.17 Individuals sick with TB strains resistant to many
drugs can still be cured with prompt treatment and a potent drug
combination.18 Inadequate treatment selects TB organisms resistant to
yet more drugs.19 These also spread by the airborne route.20
Guidance for how to cure people sick with DR-TB and stop further
spread has been available for nearly 20 years.21–24 Low and middle
income countries bear the greatest burden of TB and DR-TB.1 Richer
countries have programs to stem the spread of DR-TB, but such
programs are rare in the rest of the world.25
Between 2000 and 2009, fewer than 1 per cent of all those sick with
MDR-TB were treated with drugs of known good quality.11,26 Children
likely accounted for very few of those treated. The US Institute of
Medicine, in a series of workshops, has examined barriers and proposed
ways to get effective DR-TB treatment to all those who require it.6,8–11
Yet today, most people sick with DR-TB remain undetected and
untreated.26,27 They continue to spread DR-TB strains through the air –
to family, friends, and strangers.
Why are Children with Drug-Resistant TB Invisible?
The ‘Roadmap for childhood tuberculosis: Towards zero deaths’28 is the
latest guidance from a dedicated group of experts and advocates who,
for more than a decade, has worked to bring more systematic attention
to the plight of children affected by TB.29–31 Children sick with TB have
been neglected to the point of invisibility.28,32–36 The confluence of four
factors makes children sick with drug-resistant strains ofM. tuberculosis
even more difficult to ‘see’ and treat:
● Childhood TB is different from adult TB: Children typically have fewer
mycobacteria (bacillary burden) than adults and are more likely to have
extra-pulmonary TB.37–40 Young children have difficulty producing
testable sputum, the specimen most used for testing. Without sputum, a
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bacteriological diagnosis of M. tuberculosis, which requires viewing or
growing the TB organism, is infrequent.41 A diagnosis of TB disease in a
child can, without sputum, be assembled using a combination of clinical
(including radiographic), immunological (skin testing), and epidemiolo-
gical criteria (known contact with a person who is sick with TB).
Doctors usually decide whether to treat without a bacteriological
confirmation of M. tuberculosis and even when confirmed by culture,
treatment is begun without drug susceptibility data.42–44
● Today’s diagnostic tools are fundamentally limited.45–48 Without
isolating the organism, drug-susceptibility testing of the child’s TB
strain cannot be performed. Although growing M. tuberculosis in
culture media is the ‘gold standard’, a microscopic examination of a
specimen, usually sputum, can be useful. As it is less expensive and
requires less complex technology compared with culture, smear
microscopy has become the principal diagnostic tool in most TB
programs.49 But smear microscopy performs poorly in individuals
with low bacillary burdens – children and those with HIV co-
infection. Fewer than 20 per cent of children with TB disease will
have a smear-positive sputum test result.50 Even culture, far more
sensitive than smear microscopy, performs poorly in children: fewer
than half of children with TB disease will have M. tuberculosis
isolated in sputum cultures.51 Yet culturing the bacterium has
been a pre-requisite for testing drug susceptibility. New rapid
molecular tests (CB NAAT or Xpert MTB/Rif), designed to detect
TB disease and drug resistance without culturing, still depend on
sputum specimens.52 Despite their limitations for diagnosing chil-
dren, experts suggest these tests should be the first used for children
suspected of having TB disease and/or drug resistance.31,53
● Children sick with TB and DR-TB are under-represented in systematic
information sources.54,55 Researchers use routinely reported TB case
data to estimate disease burden. But these data are not consistently
available by age group. Data are available by age group for TB cases
detected by smear microscopy. But, as noted above, children with TB
are unlikely to be detected by this test. Two other potential sources of
data might be used to inform childhood TB estimates, but neither
includes child-specific information:
 Systematic TB prevalence surveys from many countries exclude
children (age<15 years) by design.56
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 Systematic DR-TB surveys and surveillance studies have required
positive smear microscopy test results. As children are far less likely
than adults to meet this inclusion criterion, fewer than 2 per cent of
TB cases included in systematic DR-TB surveys were children.15
It can be argued that including children in either TB or DR-TB preva-
lence surveys is not the most efficient way to improve estimates of the
childhood disease burden, but no other systematic data collection has
been used to inform robust estimates of childhood TB and DR-TB.
For the same reasons, it is exceedingly difficult to quantify how much
TB contributes to child mortality.57 A sizeable proportion of child
deaths attributed to malnutrition, pneumonia, or HIV infection may
be due to undiagnosed TB. That would make it one of the most
important causes of death in young children, worldwide.
● TB contact investigation has yet to be deployed in most of the world.
The one reliable tool for promptly finding and treating children with
TB is not used in much of the world. Contact investigation is the
systematic identification and evaluation of individuals known to be
exposed to someone sick with TB, permitting treatment of clinical
disease or treatment of latent infection (the latter is also known as
preventive therapy).21,58 Contact investigation is standard practice in
some places;23 and a cornerstone of the TB elimination strategy in the
United States.59–61 Adult and pediatric household contacts are at high
risk for both infection and disease.62,63 This is similarly true for those
living with someone sick with DR-TB.64 Recent global guidelines
emphasize contact tracing in all households of those sick with TB,65
particularly households where someone is sick with MDR-TB.1,66
Although no controlled trials have examined preventive therapy for
persons exposed to MDR-TB,67 experts who have reviewed observa-
tional data suggest management of close contacts include preventive
therapy regimens for MDR-TB.68–73
Contact investigation has, for half a century,74 been the best way to
find children newly infected with TB and those with early disease.
It remains so today.21,75–79 Unfortunately, despite global policy recom-
mendations,30,65,66 countries with high TB burdens rarely use contact
investigation.80,81 It is in these places where most children with TB live.
How often do we find TB in children living with someone who is sick
with TB? In some high-burden settings, as many as one-third of children
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had TB disease.82,83 Contact investigations can find children sick in early
stages of TB, increasing the chances of cure.84 Furthermore, preventive
therapy is highly effective in children59 and cost-effective as well.79
Failure to deploy contact investigation everywhere means we are not
using the one tool that could allow us to ‘see’ and treat promptly
otherwise invisible children sick with TB.
For more than two decades, the dominant strategy for confronting TB
in high-burden countries attempted to treat the most infectious people
and thereby prevent TB transmission to children.85 All agree that it has
failed to do so.28 To repeat, TB in children – and DR-TB in particular – is
invisible because we are systematically blinded to it by the:
● nature of childhood TB disease;
● inadequate tools available for diagnosis in children;
● inadequate data available for estimating the childhood disease
burden; and
● large-scale failure to implement the one programmatic strategy that
can efficiently ‘see’ children with TB.
Children as Sentinels of Transmission and Policy Response
Given this gloomy assessment, is there a way out of the invisibility trap?
Yes, and another peculiarity of childhood TB offers the key. A child who
is infected with TB is likely to progress to disease and death more rapidly
than an adult.86 Compared with adults, a child sick with TB is more
likely to reflect recent transmission.38,54 Children can be ‘sentinels’ for
TB. The word ‘sentinel’ originates from the Latin word sentire, ‘to
perceive’ or ‘to see’. It holds within it a fundamental and radical idea.
Children rapidly embody actionable information about the underlying
TB epidemic. Rising TB rates among children are windows on increased
transmission.86 In the United States, for example, pediatric TB rates
reflected the late 1980s’ upsurge in adult rates,87,88 and were slow to
drop even after adult rates declined.89 Many TB workers have talked of
‘sentinel events’,37,38,47 ‘Geiger counters’,74 and ‘litmus tests’90 when
referring to children sick with TB.
Children are also sentinels for drug-resistant TB. DR-TB in children
reflects the profile of strains circulating in a community.38,46,91–95
In some very high TB-burden communities, children presenting with
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DR-TB may have been infected with a DR-TB strain from someone
outside the home.96 But the few reports of children exposed to DR-TB at
home suggest they were infected from the sick person with DR-TB living
with that child.97–99
As children with DR-TB disease are the most difficult group to ‘see’
and to treat effectively, they may be ‘sentinels’, but ironically, invisible
ones. How do we go about dismantling this invisibility trap – both for
the benefit of individual children and to capture the actionable informa-
tion that can be obtained from this group?
The Sentinel Project on Pediatric Drug-Resistant TB
Will the invisibility of childhood DR-TB yield to a new collaborative
science-advocacy network that we have helped assemble? Certainly,
children sick with DR-TB constitute a small group that is more difficult
to see than other children with TB. Yet improved care for those with
DR-TB would surely mean rising quality of care for all children with TB.
The idea of ‘children as sentinels’ requires a radically different approach
to science and action against TB in all forms. Rather than expecting a
focus on infectious adults to improve outcomes and reduce risks to
children, it is time to give priority to treating sick children and preventing
disease among children at highest risk. The old strategy has been domi-
nant for more than two decades, and done little to benefit immediately
individual children.100
In October 2011 we convened colleagues to form the Sentinel Project
on Pediatric Drug-Resistant Tuberculosis, a collection of researchers,
caregivers, and advocates who shared a vision of a world where no child
dies from this curable disease.101 More than 300 individuals in more
than 60 countries are now connected as a virtual community of concern
(www.sentinel-project.org). Network members, all volunteers, collabo-
rate globally to raise the visibility of this deadly threat to children, and to
share evidence and resources that can increase prompt and effective
treatment of children. They also produce new knowledge. Within the
Sentinel Project, designated task forces take on projects, including the
following:
● Advocacy resources: The Sentinel Project gathered and disseminated
two collections of stories of children with DR-TB.102,103 It has posted
online an interactive global map to display the personal stories of
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nearly 70 children in more than 30 countries (www.sentinel-project.
org). Each individual child with DR-TB merits attention – not only
because each child requires treatment, but because each child’s story
reveals specific gaps in care delivery affecting many, many others.
● Field handbook for practitioners: We have also produced a practical
50-page field handbook for practitioners104 buttressed by a review
paper with clinical management recommendations.44 Together they
may increase practitioners’ knowledge about how to evaluate children
at risk and how to design and deliver effective drug regimens. To
disseminate the handbook and review, we have conducted several
courses, workshops, and webinars (www.sentinel-project.org).
● Definitions for pediatric DR-TB research: To promote more consis-
tent and better quality data, we have proposed definitions for use in
pediatric DR-TB research.105 We suggest a systematic approach to
classifying children as ‘probable’ cases of pediatric DR-TB, in addition
to bacteriologically confirmed child cases.
Next steps include developing research priorities focused on the needs of
children with DR-TB. To make this population more visible, we must
gather better data and apply best practices through multi-site projects.
Targets for Evaluation, Treatment, and Prevention
Improved access to care for children with DR-TB will be impossible if the
need remains invisible. Robust estimates of the DR-TB burden are hard
to create,106 and it is more difficult to do so for children. The absence of
treatment targets for children with any form of TB – as these targets
depend on disease burden estimates – remains a barrier.32,33,55 We
learned from the HIV experience. Initially estimates to project global
resource needs for HIV prevention and treatment programs were
generated with broad-stroke parameters.107,108 Advocacy efforts at the
time fundamentally depended on these. The new campaign to end child
deaths from TB28 will require putting on paper more concrete treatment
goals. Simply put: we argue that, without targets, it will be impossible to
reverse the neglect of children with TB.
Yes, even rough targets will help improve treatment access for children
with DR-TB. But is there a practical strategy? Household contact
investigation is an underused but effective tool to detect and treat sick
children promptly and efficiently. Most children will have been infected
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by their closest contacts, by those with whom they share homes.86 A
consensus exists about best practices to treat DR-TB disease in chil-
dren,44 and experience is accumulating in the use of preventive therapy
in child MDR-TB contacts.69,71–73,109
For an exercise to estimate targets, we will use the subset of children
exposed at home to MDR-TB. A set of provisional annual targets will
be updated every year. Initial parameters are listed in Table 1. The
provisional targets are listed in Table 2 by country and Table 3 by WHO
region.
To arrive at these provisional targets, we begin with official estimates
available for each country in 2012: the number of MDR-TB cases among
all notified pulmonary TB cases.1 It is important to underscore that this
is only a subset of the expected true number of individuals sick with
MDR-TB in each country.27 Because this number – MDR-TB cases
expected among notified pulmonary TB cases – is the only estimate
available consistently across countries, we use it as the starting point for
a targets framework. (See Box 1 for a summary of the simple calculations
we describe just below.)
Number of children who require evaluation: We multiply the number
of individuals with MDR-TB by an average of the number of children we
might expect to find in a household. To be conservative, we use an
average of two children per household.110 This product is a first target,
children to be enumerated and screened: 600 000 have known house-
hold exposure to someone sick with pulmonary MDR-TB. This target
comprises two groups of child contacts: those less than 5 years old and
those 5–14 years old. To estimate child contacts in the two groups,
we assumed equal distribution over age: 33.3 per cent (about 200 000)
of all child contacts would be in the younger group (0–4 year olds) and
66.7 per cent (about 400 000) in the older group (5–14 year olds). All
require complete evaluations, including at least, physical examination,
Table 1: Parameters used for estimation
Number Description of parameter Value Reference
(1) Average number of children (age less than 15 years) per household 2 OECD (2012)
(2) Proportion of child contacts age 0–4 years 0.333 —
(3) Proportion of child contacts age 5–14 years 0.666 —
(4) Proportion of TB disease in child contacts age 0–4 years 0.100 Fox (2013)
(5) Proportion of TB disease in child contacts age 5–14 years 0.084 Fox (2013)
(6) Proportion of latent TB infection in child contacts age 5–14 years 0.531 Fox (2013)
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Table 2: Estimated MDR-TB child-contact targets by country or territory, grouped by WHO region
Estimated number of MDR-
TB cases among all notified
pulmonary TB cases, 2012
Target 1 Target 2 Target 3
Number of children who
require evaluation
Number of children who
require treatment for TB
disease






























Algeria 180 120 240 360 12 20 32 108 117 225
Angola 1700 1132 2268 3400 113 190 304 1019 1103 2122
Benin 54 36 72 108 4 6 10 32 35 67
Botswana 140 93 187 280 9 16 25 84 91 175
Burkina Faso 150 100 200 300 10 17 27 90 97 187
Burundi 150 100 200 300 10 17 27 90 97 187
Cameroon 670 446 894 1340 45 75 120 402 435 836
Cabo Verde 10 7 13 20 1 1 2 6 6 12
Central African Republic 130 87 173 260 9 15 23 78 84 162
Chad 320 213 427 640 21 36 57 192 208 399
Comoros 3 2 4 6 0 0 1 2 2 4
Congo 250 167 334 500 17 28 45 150 162 312
Cote d'Ivoire 580 386 774 1160 39 65 104 348 376 724
Democratic Republic of the Congo 2900 1931 3869 5800 193 325 518 1738 1882 3620
Equatorial Guinea 0 0 0 0 0 0 0 0 0 0
Eritrea 79 53 105 158 5 9 14 47 51 99
Ethiopia 2000 1332 2668 4000 133 224 357 1199 1298 2497
Gabon 170 113 227 340 11 19 30 102 110 212
Gambia 10 7 13 20 1 1 2 6 6 12
Ghana 390 260 520 780 26 44 70 234 253 487
Guinea 250 167 334 500 17 28 45 150 162 312
Guinea-Bissau 45 30 60 90 3 5 8 27 29 56
























Lesotho 170 113 227 340 11 19 30 102 110 212
Liberia 130 87 173 260 9 15 23 78 84 162
Madagascar 170 113 227 340 11 19 30 102 110 212
Malawi 96 64 128 192 6 11 17 58 62 120
Mali 140 93 187 280 9 16 25 84 91 175
Mauritania 59 39 79 118 4 7 11 35 38 74
Mauritius 0 0 0 0 0 0 0 0 0 0
Mozambique 2000 1332 2668 4000 133 224 357 1199 1298 2497
Namibia 630 420 840 1260 42 71 113 378 409 786
Niger 270 180 360 540 18 30 48 162 175 337
Nigeria 3600 2398 4802 7200 240 403 643 2158 2336 4494
Rwanda 240 160 320 480 16 27 43 144 156 300
Sao Tome and Principe 15 10 20 30 1 2 3 9 10 19
Senegal 400 266 534 800 27 45 71 240 260 499
Seychelles 0 0 0 0 0 0 0 0 0 0
Sierra Leone 220 147 293 440 15 25 39 132 143 275
South Africa 8100 5395 10 805 16 200 539 908 1447 4855 5256 10 111
Swaziland 730 486 974 1460 49 82 130 438 474 911
Togo 77 51 103 154 5 9 14 46 50 96
Uganda 1000 666 1334 2000 67 112 179 599 649 1248
United Republic of Tanzania 510 340 680 1020 34 57 91 306 331 637
Zambia 620 413 827 1240 41 69 111 372 402 774
Zimbabwe 930 619 1241 1860 62 104 166 557 603 1161
Region of the Americas
Anguilla 0 0 0 0 0 0 0 0 0 0
Antigua and Barbuda 0 0 0 0 0 0 0 0 0 0
Argentina 340 226 454 680 23 38 61 204 221 424
Aruba 1 1 1 2 0 0 0 1 1 1
Bahamas 1 1 1 2 0 0 0 1 1 1
Barbados 0 0 0 0 0 0 0 0 0 0
Belize 3 2 4 6 0 0 1 2 2 4
Bermuda 0 0 0 0 0 0 0 0 0 0
Bolivia (Plurinational State of) 150 100 200 300 10 17 27 90 97 187
Bonaire, Saint Eustatius and Saba 0 0 0 0 0 0 0 0 0 0
Brazil 1700 1132 2268 3400 113 190 304 1019 1103 2122






























Estimated number of MDR-
TB cases among all notified
pulmonary TB cases, 2012
Target 1 Target 2 Target 3
Number of children who
require evaluation
Number of children who
require treatment for TB
disease





























Canada 7 5 9 14 0 1 1 4 5 9
Cayman Islands 0 0 0 0 0 0 0 0 0 0
Chile 19 13 25 38 1 2 3 11 12 24
Colombia 310 206 414 620 21 35 55 186 201 387
Costa Rica 6 4 8 12 0 1 1 4 4 7
Cuba 11 7 15 22 1 1 2 7 7 14
Curacao 0 0 0 0 0 0 0 0 0 0
Dominica 0 0 0 0 0 0 0 0 0 0
Dominican Republic 330 220 440 660 22 37 59 198 214 412
Ecuador 380 253 507 760 25 43 68 228 247 474
El Salvador 16 11 21 32 1 2 3 10 10 20
Grenada 0 0 0 0 0 0 0 0 0 0
Guatemala 140 93 187 280 9 16 25 84 91 175
Guyana 48 32 64 96 3 5 9 29 31 60
Haiti 390 260 520 780 26 44 70 234 253 487
Honduras 71 47 95 142 5 8 13 43 46 89
Jamaica 3 2 4 6 0 0 1 2 2 4
Mexico 480 320 640 960 32 54 86 288 311 599
Montserrat 0 0 0 0 0 0 0 0 0 0
Nicaragua 46 31 61 92 3 5 8 28 30 57
Panama 56 37 75 112 4 6 10 34 36 70
Paraguay 55 37 73 110 4 6 10 33 36 69
























Puerto Rico 1 1 1 2 0 0 0 1 1 1
Saint Kitts and Nevis 0 0 0 0 0 0 0 0 0 0
Saint Lucia 0 0 0 0 0 0 0 0 0 0
Saint Vincent and the Grenadines 1 1 1 2 0 0 0 1 1 1
Sint Maarten (Dutch part) 0 0 0 0 0 0 0 0 0 0
Suriname 3 2 4 6 0 0 1 2 2 4
Trinidad and Tobago 11 7 15 22 1 1 2 7 7 14
Turks and Caicos Islands 0 0 0 0 0 0 0 0 0 0
United States of America 81 54 108 162 5 9 14 49 53 101
Uruguay 1 1 1 2 0 0 0 1 1 1
Venezuela (Bolivarian Republic of) 100 67 133 200 7 11 18 60 65 125
Eastern Mediterranean region
Afghanistan 1300 866 1734 2600 87 146 232 779 844 1 623
Bahrain 3 2 4 6 0 0 1 2 2 4
Djibouti 81 54 108 162 5 9 14 49 53 101
Egypt 330 220 440 660 22 37 59 198 214 412
Iran (Islamic Republic of) 750 500 1001 1500 50 84 134 450 487 936
Iraq 420 280 560 840 28 47 75 252 273 524
Jordan 15 10 20 30 1 2 3 9 10 19
Kuwait 0 0 0 0 0 0 0 0 0 0
Lebanon 10 7 13 20 1 1 2 6 6 12
Libya 36 24 48 72 2 4 6 22 23 45
Morocco 300 200 400 600 20 34 54 180 195 374
Oman 6 4 8 12 0 1 1 4 4 7
Pakistan 11 000 7326 14 674 22 000 733 1233 1965 6593 7137 13 731
Qatar 6 4 8 12 0 1 1 4 4 7
Saudi Arabia 84 56 112 168 6 9 15 50 55 105
Somalia 770 513 1027 1540 51 86 138 462 500 961
South Sudan 250 167 334 500 17 28 45 150 162 312
Sudan 580 386 774 1,160 39 65 104 348 376 724
Syrian Arab Republic 97 65 129 194 6 11 17 58 63 121
Tunisia 19 13 25 38 1 2 3 11 12 24
United Arab Emirates 2 1 3 4 0 0 0 1 1 2






























Estimated number of MDR-
TB cases among all notified
pulmonary TB cases, 2012
Target 1 Target 2 Target 3
Number of children who
require evaluation
Number of children who
require treatment for TB
disease






























Albania 2 1 3 4 0 0 0 1 1 2
Andorra 0 0 0 0 0 0 0 0 0 0
Armenia 250 167 334 500 17 28 45 150 162 312
Austria 18 12 24 36 1 2 3 11 12 22
Azerbaijan 2800 1865 3735 5600 186 314 500 1678 1817 3495
Belarus 2200 1465 2935 4400 147 247 393 1319 1427 2746
Belgium 15 10 20 30 1 2 3 9 10 19
Bosnia and Herzegovina 13 9 17 26 1 1 2 8 8 16
Bulgaria 100 67 133 200 7 11 18 60 65 125
Croatia 2 1 3 4 0 0 0 1 1 2
Cyprus 2 1 3 4 0 0 0 1 1 2
Czech Republic 10 7 13 20 1 1 2 6 6 12
Denmark 3 2 4 6 0 0 1 2 2 4
Estonia 70 47 93 140 5 8 13 42 45 87
Finland 3 2 4 6 0 0 1 2 2 4
France 45 30 60 90 3 5 8 27 29 56
Georgia 630 420 840 1260 42 71 113 378 409 786
Germany 63 42 84 126 4 7 11 38 41 79
Greece 6 4 8 12 0 1 1 4 4 7
























Hungary 31 21 41 62 2 3 6 19 20 39
Iceland 1 1 1 2 0 0 0 1 1 1
Ireland 2 1 3 4 0 0 0 1 1 2
Israel 22 15 29 44 1 2 4 13 14 27
Italy 43 29 57 86 3 5 8 26 28 54
Kazakhstan 7000 4662 9338 14 000 466 784 1251 4196 4542 8738
Kyrgyzstan 1800 1199 2401 3600 120 202 322 1079 1168 2247
Latvia 120 80 160 240 8 13 21 72 78 150
Lithuania 300 200 400 600 20 34 54 180 195 374
Luxembourg 0 0 0 0 0 0 0 0 0 0
Malta 0 0 0 0 0 0 0 0 0 0
Monaco 0 0 0 0 0 0 0 0 0 0
Montenegro 0 0 0 0 0 0 0 0 0 0
The Netherlands 9 6 12 18 1 1 2 5 6 11
Norway 3 2 4 6 0 0 1 2 2 4
Poland 48 32 64 96 3 5 9 29 31 60
Portugal 35 23 47 70 2 4 6 21 23 44
Republic of Moldova 1700 1132 2268 3400 113 190 304 1019 1103 2122
Romania 800 533 1067 1600 53 90 143 480 519 999
Russian Federation 46 000 30 636 61 364 92 000 3064 5155 8218 27 572 29 847 57 420
San Marino 0 0 0 0 0 0 0 0 0 0
Serbia 20 13 27 40 1 2 4 12 13 25
Slovakia 2 1 3 4 0 0 0 1 1 2
Slovenia 0 0 0 0 0 0 0 0 0 0
Spain 31 21 41 62 2 3 6 19 20 39
Sweden 11 7 15 22 1 1 2 7 7 14
Switzerland 9 6 12 18 1 1 2 5 6 11
Tajikistan 910 606 1214 1820 61 102 163 545 590 1136
The Former Yugoslav Republic of Macedonia 5 3 7 10 0 1 1 3 3 6
Turkey 520 346 694 1040 35 58 93 312 337 649
Turkmenistan 0 0 0 0 0 0 0 0 0 0
Ukraine 6800 4529 9071 13 600 453 762 1215 4076 4412 8488
United Kingdom of Great Britain and
Northern Ireland
69 46 92 138 5 8 12 41 45 86






























Estimated number of MDR-
TB cases among all notified
pulmonary TB cases, 2012
Target 1 Target 2 Target 3
Number of children who
require evaluation
Number of children who
require treatment for TB
disease






























Bangladesh 4200 2797 5603 8400 280 471 750 2517 2725 5243
Bhutan 25 17 33 50 2 3 4 15 16 31
Democratic People’s Republic of Korea 3800 2531 5069 7600 253 426 679 2278 2466 4743
India 64 000 42 624 85 376 128 000 4262 7172 11 434 38 362 41 527 79 888
Indonesia 6900 4595 9205 13 800 460 773 1233 4136 4477 8613
Maldives 2 1 3 4 0 0 0 1 1 2
Myanmar 6000 3996 8004 12 000 400 672 1072 3596 3893 7490
Nepal 990 659 1321 1980 66 111 177 593 642 1236
Sri Lanka 21 14 28 42 1 2 4 13 14 26
Thailand 1800 1199 2401 3600 120 202 322 1079 1168 2247
Timor-Leste 82 55 109 164 5 9 15 49 53 102
Western Pacific region
American Samoa 0 0 0 0 0 0 0 0 0 0
Australia 17 11 23 34 1 2 3 10 11 21
Brunei Darussalam 0 0 0 0 0 0 0 0 0 0
Cambodia 380 253 507 760 25 43 68 228 247 474
China 59 000 39 294 78 706 118 000 3929 6611 10 541 35 365 38 282 73 647
China, Hong Kong SAR 48 32 64 96 3 5 9 29 31 60
China, Macao SAR 8 5 11 16 1 1 1 5 5 10
























Fiji 0 0 0 0 0 0 0 0 0 0
French Polynesia 0 0 0 0 0 0 0 0 0 0
Guam 0 0 0 0 0 0 0 0 0 0
Japan 240 160 320 480 16 27 43 144 156 300
Kiribati 15 10 20 30 1 2 3 9 10 19
Lao People’s Democratic Republic 220 147 293 440 15 25 39 132 143 275
Malaysia 18 12 24 36 1 2 3 11 12 22
Marshall Islands 4 3 5 8 0 0 1 2 3 5
Micronesia (Federated States of) 7 5 9 14 0 1 1 4 5 9
Mongolia 170 113 227 340 11 19 30 102 110 212
Nauru 0 0 0 0 0 0 0 0 0 0
New Caledonia 0 0 0 0 0 0 0 0 0 0
New Zealand 4 3 5 8 0 0 1 2 3 5
Niue 0 0 0 0 0 0 0 0 0 0
Northern Mariana Islands 0 0 0 0 0 0 0 0 0 0
Palau 0 0 0 0 0 0 0 0 0 0
Papua New Guinea 1100 733 1467 2200 73 123 197 659 714 1373
Philippines 12 000 7992 16 008 24 000 799 1345 2144 7193 7786 14 979
Republic of Korea 2200 1465 2935 4400 147 247 393 1319 1427 2746
Samoa 0 0 0 0 0 0 0 0 0 0
Singapore 36 24 48 72 2 4 6 22 23 45
Solomon Islands 12 8 16 24 1 1 2 7 8 15
Tokelau 0 0 0 0 0 0 0 0 0 0
Tonga 0 0 0 0 0 0 0 0 0 0
Tuvalu 1 1 1 2 0 0 0 1 1 1
Vanuatu 0 0 0 0 0 0 0 0 0 0
Viet Nam 3800 2531 5069 7600 253 426 679 2278 2466 4743





























Table 3: Estimated MDR-TB child-contact targets in six WHO regions




Target 1 Target 2 Target 3
Number of children who
require evaluation
Number of children who
require treatment for TB
disease





























South-East Asia 87 820 58 488 117 152 175 640 5849 9 841 15 690 52 639 56 982 109 622
Western Pacific 79 281 52 801 105 761 158 562 5280 8884 14 164 47 521 51 442 98 963
European 76 525 50 966 102 084 153 050 5097 8575 13 672 45 869 49 653 95 523
African 33 088 22 037 44 139 66 176 2204 3708 5911 19 833 21 469 41 302
Eastern Mediterranean 16 209 10 795 21 623 32 418 1080 1816 2896 9716 10 517 20 233
Americas 6961 4636 9286 13 922 464 780 1244 4172 4517 8689
























rapid molecular testing, and chest radiograph according to current
global guidelines.31,104
Treatment target: For the treatment target, we multiply the first
‘evaluation’ targets by the proportion of each group expected to have
TB disease. For this proportion, we use the pooled TB disease risk
estimated in the two age groups of child contacts in the 2013 systematic
review and meta-analysis of TB contact investigations, namely, 10.0 per
cent in those less than 5 years old and 8.4 per cent in those 5–14 years
old.63 The disease risk among close contacts of individuals sick with any
type of TB that is synthesized in that meta-analysis is consistent with
observations in DR-TB household contact investigations.64,68,98,99 We
then multiply the disease risk in each group by the number of child
contacts. This constitutes a treatment target: about 50 000 children
require treatment for TB disease at the time the ‘index’MDR-TB patient
is found and enrolled on treatment; about 20 000 children less than
5 years old and about 30 000 who are 5–14 years old. In both groups,
the child contacts will include some who have a bacteriological con-
firmation of TB and drug resistance. There will also be many without
bacteriological confirmation who meet the recently advanced definition
of a ‘probable’ case of TB in a child.111 Because their household
exposure was to DR-TB, these children can be classified as ‘probable’
cases of DR-TB.105 Because the child contacts in the MDR-TB
Box 1: Estimating three child-specific targets in households of MDR-TB patients
If:
M=number of notified pulmonary MDR-TB patients in one year,
the subscript a indicates children age 0–4 years, and









T3b = (T1b−T2b )×0.531
T3a+3b =T3a+T3b
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households who become sick are very likely to have MDR-TB disease,
but unlikely to have microbiological confirmation,68,98,99 effective treat-
ment for most means presumptive treatment of MDR-TB, based on
drug-susceptibility data from the individual sick with MDR-TB who is
most likely to have infected the children in that household.21,69,112
MDR-TB preventive therapy target: Finally, we calculate a third
target, the number of child contacts who should receive preventive
therapy for MDR-TB. All child contacts less than 5 years old without
TB disease are included in this target. This age-specific recommendation
is consistent with current guidelines on TB preventive therapy in child
contacts of individuals sick with TB.31 For child contacts who are 5–14
years old, we take two steps to quantify the target, those with a positive
tuberculin skin test (evidence of latent TB infection) who could benefit
from preventive therapy. First, we subtract the second target (treatment
for TB disease) from the first (evaluation target). Next, to this difference
we apply the estimate of the proportion with evidence of latent TB
infection among child contacts age 5–14 years old (53.1 per cent) from
the aforementioned systematic review and meta-analysis.63 This preven-
tive therapy target consists of nearly 400 000 children who are exposed
to or latently infected with MDR-TB and who would benefit from
preventive therapy: globally, nearly 200 000 child contacts less than
5 years old and another 200 000 who are 5–14 years old. Preventive
therapy regimens for both groups of child contacts could be designed
according to expert guidance, based on growing observational evidence
of benefit and safety.68–73 If any drug or drug combination can come
even close to the spectacular efficacy of isoniazid for treating isoniazid-
susceptible latent TB infection in children,59,113 then it will avert every
year large numbers of child cases and deaths due to DR-TB.
Utility of a Targets Framework
We present a set of provisional country-level targets of child household
contacts (Table 2) by WHO region in Table 3. The targets in two age
groups indicate the numbers of: (i) children who require complete
evaluation for TB disease and infection; (ii) children who require
treatment for TB disease; and (iii) children who would benefit from
preventive therapy. These are actionable targets for a single year: an
approximation of how many children exposed to MDR-TB could be
found and started on treatment using household contact investigations.
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The shortcomings of these ‘back-of-the-envelope’ estimates are sev-
eral. First, we started with estimates of MDR-TB among notified
pulmonary TB cases in a year rather than all MDR-TB cases estimated
to occur in that year. Yet our estimated target of child contacts with
MDR-TB disease in a year exceeds other recent estimates that put the
number of children with MDR-TB around 32 000 globally.3 They were
lower because they used routine TB notifications and existing estimates
of global incidence as inputs. Possible biases in those inputs could result
in underestimation of childhood disease. To get a sense of how many
child contacts would need to be screened in a year, our targets frame-
work begins with an estimate of the number of pulmonary MDR-TB
cases we expect would be notified in each country.
Second, we applied a single median for the number of children per
household, yet the median number of children per household is variable
and higher in most countries with larger populations and also in those
with higher TB incidence.
Finally, we applied a single estimate of disease risk in each of two age
groups of child contacts. But we know that disease risk varies within the
age groups.114 The average risk of TB disease among child contacts may
be higher than the proportion we applied, exceeding in some settings a
third of all the children in the home.82,83
For all these reasons, this first set of provisional targets is likely to
underestimate the number of children who could be found through MDR-
TB household contact investigations and who require screening and care.
Notwithstanding the limitations, our exercise produces a simple
framework with pragmatic value: First, it provides a sense of the magni-
tude of the problem in understandable terms. Knowing the absolute
numbers of sick children in a single year in identifiable households might
serve to galvanize attention more effectively than the idea of TB elimi-
nation decades in the future. Short-term, 1-year targets are useful for
communicating with diverse interested parties seeking to develop joint
strategies. The number of child cases treated or prevented serves as a key
indicator of the quality for any strategy. With better data, this simple
framework could be used at many levels (community, sub-national,
national) to build a shared vision, a vision that can galvanize new
collaborative actions to reach short-term targets.
Second, our framework highlights concrete gaps in action. It reminds
us that there is one effective tool not currently used widely to stop disease
and deaths in children: TB contact investigation. Other interventions
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exist whose potential can be tapped to prevent TB disease and death in
both women and young children.115–119 Contact investigation in TB
patient households constitutes an effective screening strategy to find
more TB cases;65 it is also high yield in the households of individuals sick
with DR-TB.64 The highest yields should be expected among the young-
est children,84 who are the least likely to be recognized as TB cases
without contact investigation. Given sufficient resources, we can begin
immediately to screen child contacts and provide TB treatment.
Third, the framework points to critical gaps in knowledge, and
can drive an ambitious scientific agenda that gives children priority.
The lack of a tool that can reliably detect TB infection, disease, and drug
resistance in children is a major gap. Treatment for children with
MDR-TB disease can have good outcomes, but has yet to be optimized.
Can today’s regimens be shortened and otherwise simplified, without
compromising efficacy? A lack of child-friendly formulations of key
drugs restricts treatment.120 Evidence suggests that preventive therapy in
children exposed to DR-TB is effective.68,71,72 But what is the optimal
approach? Children at high risk for DR-TB disease and infection, like
those who live with an adult sick with DR-TB, are a high-yield, high-
priority population for demonstrating the value of any new test, vaccine,
or preventive regimen.
In sum, this framework is a tool for convening interested parties to act
jointly toward shared targets. It can reinforce collaborative efforts to
apply existing knowledge immediately and produce new knowledge.
Enumerating cohorts of household members of MDR-TB patients for
evaluation – and then applying all existing tools – would itself break
from the past and serve as a ‘pilot’ for optimizing contact investigations
around all TB patients, not only those with MDR-TB. Monitoring
progress on the proposed targets can inform efforts against the larger
global TB pandemic. Most importantly, children will no longer be an
afterthought; finding and treating children will be at the core by design.
Conclusions
The global burden of DR-TB in children is invisible. No easy solution
exists. The confluence of four factors has produced the invisibility:
● the nature of pediatric TB;
● our wholly inadequate armamentarium of diagnostic tools;
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● the absence of data to inform robust disease burden estimates; and
● a large-scale failure to deploy TB contact investigations.
Fortunately, the nature of pediatric TB also offers clues to solving the
problem: each child with DR-TB is a sentinel event, both for recent
transmission and for opportunities to improve TB care.
To raise the visibility of children with DR-TB, a collaborative network,
the Sentinel Project on Pediatric Drug-Resistant Tuberculosis, is building
on the concept of TB cases in children as sentinel events. We propose a
first set of treatment and prevention targets – among children exposed at
home toMDR-TB – to begin monitoring gaps in TB care and to spur new
collective actions. Setting these child-focused targets, although imperfect,
promotes a focus on actionable information. Working jointly to meet
short-term targets, we may move away from strategies that have
persistently failed children sick with TB. Efforts to meet and update these
new targets can forge a policy response to the global pandemic of DR-TB.
It will ensure that children with DR-TB are no longer invisible.
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